The IA-DUET study aimed to compare azole-echinocandin combination with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

中文翻译：

---

侵袭性曲霉菌病的优效性试验：IA-DUET （HOVON502） 试验的严酷现实检查


IA-DUET 研究旨在比较唑类-棘白菌素联合唑类单药治疗侵袭性曲霉菌病。当唑类药物耐药性未知时，患者不合格、竞争研究和支持联合治疗的指南阻碍了招募。低 IA 归因死亡率表明，未来的试验可能受益于整群随机化或复合终点以提高效率。